The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT02695810

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02695810
Other papers using this trial's data
  • The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial Diabetologia, 2021-01 DOI, PubMed 33064182

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02695810. Randomized; no masking; primary purpose prevention. Start 2016-02-24 (actual); primary completion 2018-09-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes
Condition
Prediabetic State
Condition
Obesity
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Metformin
Intervention (Behavioral)
Exercise
Lead sponsor
Steno Diabetes Center Copenhagen (class: other)
Collaborator
The Novo Nordic Foundation (class: other)
Collaborator
Copenhagen University Hospital, Rigshospitalet (class: other)
Collaborator
AstraZeneca (class: industry)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct02695810
Content hash
c677c743ba3bc3211825c332c5719d57399d0ec75bb0580a8bb10be581451183